Ligand validation:3ZNL

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3ZNL designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3ZNL_NAG_E_1023	58%	45%	0.136	0.914	0.5	1.58	-	3	1	0	100%	0.9333
3ZNL_NAG_C_1023	49%	49%	0.139	0.884	0.55	1.4	-	3	1	0	100%	0.9333
3ZNL_NAG_A_1023	46%	43%	0.157	0.892	0.58	1.6	-	3	1	0	100%	0.9333
3ZNL_NAG_C_1165	40%	42%	0.161	0.87	0.62	1.6	-	6	0	0	100%	0.9333
3ZNL_NAG_B_1154	37%	46%	0.197	0.896	0.45	1.6	-	1	0	1	100%	0.9333
3ZNL_NAG_A_1165	37%	48%	0.165	0.861	0.63	1.35	-	1	0	0	100%	0.9333
3ZNL_NAG_F_1154	33%	47%	0.195	0.876	0.47	1.54	-	1	0	1	100%	0.9333
3ZNL_NAG_E_1165	30%	45%	0.158	0.822	0.64	1.46	-	3	0	0	100%	0.9333
3ZNL_NAG_D_1154	23%	49%	0.231	0.852	0.46	1.47	-	1	0	1	100%	0.9333
4BH0_NAG_A_1320	84%	50%	0.074	0.935	0.49	1.4	-	2	0	0	100%	0.9333
4CR0_NAG_A_1165	83%	51%	0.112	0.97	0.49	1.37	-	1	0	0	100%	0.9333
4KDQ_NAG_E_502	81%	59%	0.104	0.957	0.53	1.02	-	2	2	0	100%	0.9333
4BGZ_NAG_C_503	71%	53%	0.082	0.901	0.45	1.34	-	2	0	0	100%	0.9333
4K64_NAG_A_601	70%	61%	0.125	0.942	0.51	0.97	-	1	0	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.